Kiniksa Pharmaceuticals Conference Call Summary Company Overview - **Company**: Kiniksa Pharmaceuticals International (NasdaqGS: KNSA) - **Event**: FY Conference on March 02, 2026 - **Key Speakers**: Sanj Patel (Chairman and CEO), Ross Moat (COO), John Paolini (CMO) Key Points Industry and Product Focus - **Primary Product**: ARCALYST, an IL-1 alpha and beta inhibitor for treating recurrent pericarditis - **Market Opportunity**: 18% penetration in the multiple recurrence patient group, with a total target market of 14,000 patients with multiple recurrences and an additional 26,000 patients experiencing their first recurrence [4][20][21] Financial Performance - **2025 Revenue**: Cumulative net revenue of $677.6 million, representing a 62% year-over-year growth [4] - **2026 Guidance**: Expected cumulative net revenue of $920 million, indicating continued growth [6] Growth Drivers - **Key Growth Factors**: - Increased patient additions and prescriber engagement - Higher rates of repeat prescriptions from physicians - Improved understanding of recurrent pericarditis as a chronic condition, leading to longer treatment durations [5][25] - Strong payer approval rates supporting commercial fundamentals [5] Marketing and Sales Strategy - **Sales Strategy**: Focus on digital marketing and AI initiatives to enhance prescriber education and patient engagement [19][36] - **Prescriber Engagement**: Over 4,150 unique prescribers identified, with a goal to reach the estimated 20,000-30,000 prescribers treating recurrent pericarditis [34] Treatment Paradigm Shift - **Changing Treatment Approaches**: Physicians are increasingly viewing recurrent pericarditis as a chronic condition requiring long-term treatment rather than episodic care [25][39] - **ARCALYST's Role**: Positioned as a preferred treatment option after NSAIDs and colchicine, especially for patients with severe symptoms or risk factors [39][40] Pipeline Developments - **KPL-387**: Phase 2 data expected in the second half of 2026, with plans to move into Phase 3 based on positive outcomes [59][60] - **KPL-1161**: Ongoing development with potential for indication expansion, though details remain undisclosed [72][74] Cash Flow and Investment Strategy - **Cash Utilization**: Focus on expanding KPL-387 and KPL-1161, while also considering potential acquisitions to enhance the portfolio [76][77] - **Pragmatic Approach**: The company emphasizes careful capital allocation and value creation, having successfully divested non-core assets in the past [77][78] Investor Insights - **Underappreciated Aspects**: The growth potential of KPL-387 and KPL-1161, along with the sustained success of ARCALYST, are highlighted as key areas that investors may overlook [79] Additional Considerations - **Q1 Expectations**: Anticipated headwinds due to payer plan changes and co-pay resets typical for the first quarter, which may impact gross-to-net revenue [28][31] - **Patient Characteristics**: Ongoing research into identifying patients who may benefit from early intervention with ARCALYST based on risk factors [51][52] This summary encapsulates the critical insights from the Kiniksa Pharmaceuticals conference call, focusing on the company's performance, strategic initiatives, and market opportunities.

Group 1 - Wedbush analyst David Nierengarten raised the price target on Kiniksa (KNSA) to $53 from $50 while maintaining an Outperform rating on the shares [1] - Arcalyst net product revenue reached $202.1 million in Q4 and $677.6 million for FY25, aligning with pre-announcement expectations and exceeding prior estimates [1] - The revenue growth reflects continued expansion in prescriber breadth and depth, as well as longer duration of therapy [1]

Group 1 - Kiniksa Pharmaceuticals will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 3:10 p.m. Eastern Time [1] - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible within approximately 48 hours after the event [2] - Kiniksa is focused on developing novel therapies for debilitating diseases, particularly in cardiovascular indications, with a portfolio based on strong biologic rationale [3]

Drug Development and Approval - ARCALYST received FDA approval for recurrent pericarditis in March 2021, targeting an estimated 40,000 patients in the U.S. with this condition[25]. - The FDA granted Orphan Drug Designation to KPL-387 for pericarditis treatment in October 2025[29]. - The company plans to initiate a Phase 1 clinical trial for KPL-1161, a modified version of KPL-387, by the end of 2026[30]. - The KPL-387 investigational drug is in Phase 2/3 trials, with data expected in the second half of 2026, aiming to provide a monthly self-administration option for recurrent pericarditis[62][68]. - KPL-1161, a modified version of KPL-387, is in preclinical development, designed for quarterly subcutaneous dosing, with a Phase 1 trial planned by the end of 2026[75]. - The company is exploring additional indications for ARCALYST, including a collaborative study for cardiac sarcoidosis with The Mayo Clinic[44]. - A collaborative study with The Mayo Clinic and Johns Hopkins University is underway to evaluate ARCALYST's efficacy in treating cardiac sarcoidosis over 24 weeks[49]. Commercialization and Market Strategy - The commercialization strategy for ARCALYST includes expanding awareness and establishing it as a first-line therapy for recurrent pericarditis[35]. - The company has established a commercial strategy to increase awareness and access to ARCALYST, supported by a specialty salesforce and patient advocacy collaborations[53][54]. - The company aims to maximize the potential of its pipeline through strategic collaborations and out-licensing opportunities[40]. - The commercial team has been established since March 2021 to expand ARCALYST's market presence in the U.S., focusing on patients with significant unmet medical needs[81]. Financial Agreements and Collaborations - The company received an upfront payment of $80.0 million from Genentech for the license agreement related to vixarelimab[95]. - The company is eligible to receive up to approximately $570.0 million in additional contingent payments from Genentech, including development, regulatory, and sales-based milestones[95]. - The company received a total upfront cash payment of $22.0 million from Huadong for the exclusive rights to develop and commercialize ARCALYST in the Huadong Territory[99]. - Following a regulatory milestone, Huadong became obligated to make an additional cash payment of $20.0 million, received in Q1 2025[99]. - The company remains eligible to receive up to approximately $50.0 million in sales-based milestone payments for ARCALYST from Huadong[99]. - The company has entered into a license agreement with Regeneron to develop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa[103]. - The company paid $32.5 million in upfront fees and regulatory milestone achievements under the Regeneron Agreement, sharing profits from ARCALYST sales with Regeneron after deducting specific costs[104]. Regulatory Environment and Compliance - The company is subject to extensive government regulations for drug development, requiring significant time and financial resources for compliance and approval processes[116]. - The FDA typically reviews most Biologics License Applications (BLAs) within ten months from the filing date, or six months for priority reviews, subject to extensions[128]. - The FDA may require additional clinical data before approving a BLA, issuing either an approval letter or a Complete Response Letter (CRL) indicating deficiencies[131]. - Orphan Drug designation provides financial incentives such as grant funding opportunities and tax advantages, and grants seven years of exclusivity for the first approved product for a rare disease[134]. - The FDA may designate products for expedited review if they address unmet medical needs, including Fast Track and Breakthrough Therapy designations, which allow for more frequent interactions with the FDA[136][138]. - The company is subject to various federal and state laws regarding healthcare fraud and abuse, including anti-kickback and false claims laws, which could adversely affect its reputation and financial results[182]. - The company must comply with complex reporting requirements under the Medicaid Drug Rebate Program (MDRP), which includes paying rebates for each unit of product reimbursed under state Medicaid programs[191]. Employee and Organizational Structure - As of December 31, 2025, the company had 366 full-time employees, with 351 located in the United States and 15 outside the United States[214]. - The company provides competitive base salaries, cash bonus opportunities, equity awards, and a robust benefits package, including comprehensive health insurance and a 401(k) plan with partial company match[215]. - The company emphasizes compliance, quality, and ethics, requiring all employees to confirm understanding and compliance with policies, including anti-bribery and anti-corruption measures[216]. - A comprehensive safety program and emergency response plan have been implemented to ensure health and safety across the company[217]. Market Access and Pricing Challenges - Significant uncertainty exists regarding the coverage and reimbursement status of approved biological products, with third-party payors increasingly challenging prices and examining cost-benefit analyses[189]. - The Inflation Reduction Act (IRA) of 2022 includes changes aimed at addressing rising prescription drug prices, with the first set of negotiated Medicare maximum fair prices set to take effect in 2026[198]. - The company faces increased administrative and compliance burdens due to changes in Medicaid effective in 2024, including the elimination of the Medicaid rebate cap[199]. - The EU's Health Technology Assessment (HTA) regulation, effective from January 2025, aims to enhance cooperation among member states in assessing health technologies and will impact pricing and reimbursement decisions[208]. - The company must navigate varying drug pricing and reimbursement regulations across different jurisdictions, which can significantly affect market access and profitability[190]. - Recent legislative efforts in the U.S. focus on increasing transparency in drug pricing and reducing prescription drug costs, which may impact the company's pricing strategies[202].

Core Insights - Kiniksa Pharmaceuticals is focusing on expanding the adoption of ARCALYST for recurrent pericarditis, with plans for physician education and marketing initiatives to support earlier use in the disease course [1][4] - The company has set a net revenue guidance of $900 million to $920 million for 2026, despite facing seasonal headwinds in the specialty drug sector [2] - ARCALYST product revenue saw a significant increase of 65% year-over-year to $202.1 million in Q4 2025, contributing to a full-year revenue of $677.6 million, marking the highest year-on-year growth to date [3][14] Commercial Performance - The number of prescribers for ARCALYST exceeded 4,150 by the end of 2025, with approximately 29% prescribing it for two or more recurrent pericarditis patients [4] - Market penetration for the two-plus recurrence target market rose to about 18% by the end of 2025, up from 15% mid-year and 13% at the end of 2024 [5] - Approximately 20% of ARCALYST prescriptions are now written after a first recurrence, indicating a shift towards earlier treatment [6] Pipeline Developments - Kiniksa initiated a phase II/III clinical trial for KPL-387 in recurrent pericarditis in mid-2025, with phase II data expected in the second half of 2026 [7][8] - KPL-387 aims to enhance market penetration through monthly dosing with an auto-injector, with 75% of recurrent pericarditis patients preferring its target product profile [11] - KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, is expected to enter clinical trials by the end of 2026 [12] Financial Overview - Kiniksa reported a net income of $14.2 million in Q4 2025, a turnaround from a net loss of $8.9 million in the prior-year quarter, with a full-year net income of $59.0 million compared to a net loss of $43.2 million in 2024 [14] - Operating expenses increased due to higher costs associated with ARCALYST growth and investments in commercialization [13] - The company ended 2025 with $414.1 million in cash, indicating strong liquidity and a positive cash flow outlook [15]

Financial Data and Key Metrics Changes - Arcalyst product revenue grew 65% year-over-year to $202.1 million in Q4 2025, and 62% to $677.6 million for the full year 2025 [5][17] - Net income was $14.2 million in Q4 2025, compared to a net loss of $8.9 million in Q4 2024, and net income for the full year 2025 was $59 million, compared to a net loss of $43.2 million for the full year 2024 [17][18] - Cash at the end of 2025 was $414.1 million, representing $170.4 million of net cash generation for the year [19] Business Line Data and Key Metrics Changes - The primary driver of revenue growth was the expanding adoption of interleukin-1 alpha and beta inhibition with Arcalyst as a second-line treatment [9] - The average total duration of therapy for Arcalyst is approaching three years, with robust payer approval rates and strong patient adherence [12] Market Data and Key Metrics Changes - At the end of 2025, more than 4,150 prescribers had written a prescription for Arcalyst, with around 29% prescribing it for two or more recurrent pericarditis patients [11] - Penetration into the 2-plus recurrence target market increased to approximately 18% at the end of 2025, compared to around 15% in mid-2025 and 13% at the end of 2024 [13] Company Strategy and Development Direction - The company aims to unlock the next phase of growth for Arcalyst by driving further physician awareness and advancing digital marketing initiatives [11] - KPL-387 is expected to address key patient needs and expand market penetration by potentially enabling monthly dosing with an auto-injector [7][55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of Arcalyst and the potential for KPL-387 to further enhance market presence [20] - The company is focused on creating additional value through investments in R&D and advancing internally discovered assets [6] Other Important Information - The company has maintained a strong balance sheet while advancing both its commercial business and clinical portfolio [16] - The development program for KPL-387 is on track, with data expected in the second half of 2026 [47] Q&A Session Summary Question: What do you think the peak penetration is for Arcalyst in the multiple recurrent setting? - Management has not commented on peak penetration but believes there is significant growth potential remaining [22][23] Question: Is the pace of growth in first recurrence versus multiple recurrences the same? - The percentage of patients in the first recurrence group has grown, and management views this as a positive change [28][29] Question: What is the extent of FDA interactions for KPL-387? - The company values its interactions with the FDA and has laid out a comprehensive development program for KPL-387 [34][39] Question: Are there differences in persistence rates between first and multiple recurrence populations? - No meaningful differences in persistence rates have been observed between the two populations [40][41] Question: How are you thinking about enrollment for the Phase III study of KPL-387? - Data from the Phase II portion is expected in the second half of 2026, with plans for a Phase III study to follow [46][47] Question: Will the label and potential reimbursement access for KPL-387 be similar to Arcalyst? - The KPL-387 program is designed to support a similar indication statement as Arcalyst, focusing on treating all patients with recurrent pericarditis [50][51]

Financial Data and Key Metrics Changes - ARCALYST product revenue grew 65% year-over-year to $202.1 million in Q4 2025, and 62% to $677.6 million for the full year 2025 [5][17] - Net income was $14.2 million in Q4 2025, compared to a net loss of $8.9 million in Q4 2024, and net income for the full year 2025 was $59 million, compared to a net loss of $43.2 million for the full year 2024 [17][18] - Cash at the end of 2025 was $414.1 million, representing $170.4 million of net cash generation for the year [19] Business Line Data and Key Metrics Changes - The primary driver of revenue growth was the expanding adoption of interleukin-1 alpha and beta inhibition with ARCALYST as a second-line treatment [9] - The average total duration of therapy for ARCALYST is approaching three years, with robust payer approval rates and strong patient adherence [12] Market Data and Key Metrics Changes - At the end of 2025, ARCALYST had over 4,150 prescribers, with around 29% prescribing for two or more recurrent pericarditis patients [11] - Penetration into the two-plus recurrence target market increased to approximately 18% at the end of 2025, compared to around 15% in mid-2025 and 13% at the end of 2024 [13] Company Strategy and Development Direction - The company aims to unlock the next phase of growth for ARCALYST by driving further physician awareness and advancing digital marketing initiatives [11] - KPL-387 is expected to address key patient needs and expand market penetration by potentially enabling monthly dosing with an auto-injector [7][54] - The company is focused on both ARCALYST and advancing its clinical portfolio to bring additional therapies to patients suffering from debilitating diseases [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of ARCALYST and the potential for KPL-387 to capture additional market share [5][9] - The company is optimistic about the future, emphasizing the importance of ongoing investments in R&D and commercialization efforts [6][20] Other Important Information - The company reported that ARCALYST revenue growth has been profitable since Q4 2021, allowing for strategic investments in sales and marketing [6] - The company expects to remain cash flow positive on an annual basis under its current operating plan [19] Q&A Session Summary Question: What do you think the peak penetration is for ARCALYST in the multiple recurrent setting? - Management has not commented on peak penetration but believes there is significant growth potential remaining [23] Question: Is the pace of growth in first recurrence versus multiple recurrence patients the same? - The percentage of first recurrence patients has grown, and management views this as a positive change as physicians become more comfortable prescribing ARCALYST [29] Question: What is the extent of FDA interactions for KPL-387? - The company values its interactions with the FDA and has laid out a comprehensive development program for KPL-387 [38] Question: Are there differences in persistence rates between first recurrence and multiple recurrence populations? - No meaningful differences in persistence rates have been observed between the two populations [40] Question: How are you thinking about the enrollment curve for the phase III study of KPL-387? - Data from the Phase II portion of the trial is expected in the second half of 2026, with plans for a phase III study thereafter [46]

Financial Data and Key Metrics Changes - Arcalyst product revenue grew 65% year-over-year to $202.1 million in Q4 2025, and 62% to $677.6 million for the full year 2025 [4][16] - Net income was $14.2 million in Q4 2025, compared to a net loss of $8.9 million in Q4 2024, and net income for the full year 2025 was $59 million, compared to a net loss of $43.2 million for 2024 [17][18] - Cash at the end of 2025 was $414.1 million, representing $170.4 million of net cash generation for the year [19] Business Line Data and Key Metrics Changes - The primary driver of revenue growth was the expanding adoption of interleukin-1 alpha and beta inhibition with Arcalyst as a second-line treatment [9] - Arcalyst collaboration profit grew 83% to $140 million in Q4 2025, and up 96% to $459 million for the full year 2025 [18] Market Data and Key Metrics Changes - At the end of 2025, more than 4,150 prescribers had written a prescription for Arcalyst, with around 29% prescribing it for two or more recurrent pericarditis patients [11][12] - Penetration into the 2-plus recurrence target market increased to approximately 18% at the end of 2025, compared to around 15% in mid-2025 and 13% at the end of 2024 [13] Company Strategy and Development Direction - The company aims to unlock the next phase of growth for Arcalyst by driving further physician awareness and advancing digital marketing initiatives [11] - KPL-387 is expected to address key patient needs and expand market penetration by potentially enabling monthly dosing with an auto-injector [6][52] - The company is focused on both Arcalyst and advancing its clinical portfolio to bring additional therapies to patients [20][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of Arcalyst and the potential for KPL-387 to further enhance market presence [20] - The company anticipates full year net revenue guidance for 2026 to be between $900 million and $920 million [9] Other Important Information - The company has maintained a strong balance sheet while advancing its commercial business and clinical portfolio [15] - The average total duration of therapy for Arcalyst is approaching three years, with robust payer approval rates and strong patient adherence [12] Q&A Session Summary Question: What do you think the peak penetration is for Arcalyst in the multiple recurrent setting? - Management has not commented on peak penetration but believes there is significant growth potential remaining [22][23] Question: Is the pace of growth in first recurrence versus multiple recurrences the same? - The percentage of patients in the first recurrence group has grown, and management views this as a positive change [28][30] Question: What is the extent of FDA interactions regarding KPL-387? - The company has had productive interactions with the FDA and is focused on assembling robust development packages [34][37] Question: Are there differences in persistence rates between first recurrence and multiple recurrences? - No meaningful differences have been observed between the two populations regarding persistence rates [39][40] Question: How are you thinking about enrollment for the Phase III trial of KPL-387? - Data from the Phase II portion is expected in the second half of 2026, with plans for a Phase III trial thereafter [45]

Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution F EB RUARY 24, 2026 Agenda Introduction | Sanj K. Patel, Chief Executive Officer IL-1α & IL-1β Inhibition Franchise | Ross Moat, Chief Operating Officer Fourth Quarter and Full Year 2025 Financial Results | Mark Ragosa, Chief Financial Officer Closing Remarks | Sanj K. Patel, Chief Executive Officer Q&A Session 2 Forward Looking Statements This presentation (together with any other statements or information that we may make i ...

Core Insights - Kiniksa Pharmaceuticals reported significant growth in ARCALYST sales, achieving $677.6 million in net product revenue for the full year 2025, a 62% increase year-over-year [3][7] - The company expects ARCALYST net product revenue to reach between $900 million and $920 million in 2026 [3][12] - Kiniksa has a robust financial position with a cash balance of $414.1 million as of December 31, 2025, up from $243.6 million in 2024 [12][26] Financial Results - For Q4 2025, Kiniksa reported net product revenue of $202.1 million, compared to $122.5 million in Q4 2024 [7][8] - Total revenue for the full year 2025 was $677.6 million, an increase from $423.2 million in 2024 [12][23] - The company recorded a net income of $14.2 million for Q4 2025, a turnaround from a net loss of $8.9 million in Q4 2024, and a net income of $59.0 million for the full year 2025 compared to a net loss of $43.2 million in 2024 [12][23] Product Development - Kiniksa is advancing its clinical pipeline with KPL-387, a Phase 2/3 trial for recurrent pericarditis expected to yield data in the second half of 2026 [3][7] - The company plans to initiate a Phase 1 trial for KPL-1161 by the end of 2026, which is an Fc-modified monoclonal antibody targeting IL-1 receptor [5][12] Market Position - ARCALYST has become the preferred second-line treatment for recurrent pericarditis, contributing to its sales growth [3][4] - As of the end of Q4 2025, approximately 18% of the 14,000 multiple-recurrence patients were actively on ARCALYST treatment, indicating strong market adoption [7][12]